Assertio announces results of rolvedon® (eflapegrastim-xnst) injection same-day dosing clinical study

Lake forest, ill., dec. 13, 2024 (globe newswire) -- assertio holdings, inc. (“assertio” or the “company”) (nasdaq: asrt), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (esbc).
ASRT Ratings Summary
ASRT Quant Ranking